AbCellera Biologics Inc. (ABCL)

AbCellera Biologics Operating Metrics

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020
Number of Discovery Partners	-	-	-	-	-	46.00	42.00	41.00	41.00	40.00	38.00	38.00	36.00
Number of Discovery Partners Growth	-	-	-	-	-	15.00%	10.53%	7.89%	13.89%	11.11%	8.57%	15.15%	24.14%
Number of Molecules in the Clinic	16.00	16.00	14.00	14.00	13.00	13.00	10.00	9.00
Number of Molecules in the Clinic Growth	23.08%	23.08%	40.00%	55.56%	44.44%	62.50%	42.86%	50.00%
Partnered Program Starts	-	-	-	-	-	404.00	392.00	374.00	356.00	339.00	342.00	319.00	291.00
Partnered Program Starts Growth	-	-	-	-	-	19.17%	14.62%	17.24%	22.34%	29.89%	45.53%	47.00%	41.95%
Programs Under Contract	-	-	-	-	-	203.00	182.00	177.00	177.00	174.00	164.00	164.00	158.00
Programs Under Contract Growth	-	-	-	-	-	16.67%	10.98%	7.93%	12.03%	11.54%	5.81%	18.84%	32.77%

Revenue by Segment

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020
Research Fees	20.58M	26.28M	30.26M	30.38M	34.76M	35.56M	38.24M	39.33M
Research Fees Growth	-40.80%	-26.08%	-20.86%	-22.75%	-17.31%	-12.86%	12.04%	23.89%
Licensing	1.04M	1.05M	953.00K	921.00K	777.00K	969.00K	948.00K	916.00K
Licensing Growth	33.33%	8.26%	0.53%	0.55%	-7.17%	39.22%	58.53%	44.48%
Milestone Payments	-	-	-	1.75M	-	1.50M	-	-
Milestone Payments Growth	-	-	-	-	-	66.67%	-	-

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.